BRCA2 and prostate cancer: By associating MuAt features with driver events identified in PCAWG, MuAt highlighted prostate cancers driven by SPOP mutations [59], characterized by a 2.3-fold increase in somatic SV burden, exceeding the relative burden in tumours with BRCA1 and BRCA2 mutations.